We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Investors

Bioxodes is a Belgian private clinical stage company, founded in 2013. The Company has received fundings from both public and private investors and institutional investors and is now looking for Series B funding.

Why Invest

Bioxodes at the Sachs Forum 2026

CEO Marc Dechamps on BIOX‑101, intracerebral hemorrhage, and the company’s path forward.

In this presentation from the Sachs Forum (March 2026), Bioxodes CEO Marc Dechamps outlines the company’s strategy to address the urgent unmet medical need in intracerebral hemorrhage (ICH), the science behind BIOX‑101, and the rationale supporting its clinical and commercial potential.

Investors

Public & private investors

Private Equity
(Euros)

27 million
27 million

Grants/subsidies from the Walloon Region
(Euros)

12 million
12 million

Investors

Who invests?

Investors

Why invest?

Invest in us

  • First-in-class lead compound with solid preclinical and Phase 1 clinical data, now supported by compelling interim data from the ongoing Phase 2a trial in intracerebral hemorrhage (ICH).

  • Discovery program for innovative pipeline to extend value capture beyond thrombo-inflammation.

  • Leadership and expertise with international advisor network.

  • Patent portfolio wholly owned with coverage beyond 2040.

Investors

Invest in us

Get in touch and explore our investment opportunities

investment@bioxodes.com